Retinitis Pigmentosa Clinical Trials

Find Retinitis Pigmentosa Clinical Trials Near You

Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and Adolescents

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

The goals of this observational study are to develop and train artificial intelligence (AI) algorithms using multimodal imaging to identify patients with inherited retinal degeneration (IRD) caused by Retinal Pigment Epithelium Specific Protein 65 (RPE65) and Retinitis Pigmentosa GTPase Regulator (RPGR) mutations. Another algorithm will be developed to measure and monitor retinal changes over time, with the aim of helping identify patients who may be suitable for available or emerging treatments and supporting assessment of disease progression and treatment response. The main questions this study aims to answer are: 1. Can AI algorithms accurately distinguish patients with RPE65- or RPGR-associated IRDs from individuals without these conditions using ultra-widefield retinal imaging? 2. Can AI algorithms accurately detect and quantify retinal abnormalities associated with these conditions and monitor their progression over time on ultra-widefield retinal imaging? Researchers will compare retinal images from patients with RPE65- or RPGR-associated IRDs with images from healthy participants, including people with and without myopia, to assess how accurately the algorithms can distinguish between these groups and monitor disease-related changes.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 50
Healthy Volunteers: t
View:

⁃ Participants must meet the criteria for one of the following study cohorts:

• Retinal Pigment Epithelium Specific Protein 65 (RPE65)-associated retinal degeneration: genetically confirmed biallelic sequence variants in RPE65.

• Participants with a clinical diagnosis of Leber congenital amaurosis or early onset severe retinal degeneration whose phenotype is suggestive of biallelic RPE65-associated retinal degeneration will also be eligible for inclusion.

• Retinitis Pigmentosa GTPase Regulator (RPGR)-associated retinal degeneration: genetically confirmed hemizygous RPGR sequence variants in male participants, or female participants with single heterozygous RPGR sequence variants or homozygous or compound heterozygous RPGR sequence variants will be included in this cohort.

• Participants with a clinical diagnosis of X-linked Retinitis Pigmentosa and X-linked cone-rod degeneration whose phenotype is suggestive of RPGR-associated retinal degeneration will also be eligible for inclusion.

• Control cohorts: participants without inherited retinal degeneration, including both myopic (defined as mean spherical equivalent refractive error of ≤ -1.00 dioptres (D)) and non-myopic individuals. All will be from diverse ethnic backgrounds, for development of a normative retinal imaging dataset.

• Availability of retinal imaging data of sufficient quality for the planned analyses.

Locations
United States
Massachusetts
Massachusetts Eye and Ear
NOT_YET_RECRUITING
Boston
Other Locations
Germany
TransMIT Centre of Translational Ophthalmology c/o Justus-Liebig-University Giessen
COMPLETED
Laubach
United Kingdom
UCL Institute of Ophthalmology
RECRUITING
London
Contact Information
Primary
Nikolas Pontikos, PhD, MSci, MEng, FBCS
n.pontikos@ucl.ac.uk
+44 207608 6800
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 4887
Treatments
Inherited Retinal Degeneration Associated With Biallelic RPE65 Mutations cohort
Participants with genetically confirmed biallelic pathogenic or likely pathogenic sequence variants in RPE65 will be included in this cohort. Some of the participants may have received therapy in the form of gene augmentation with voretigene neparvovec. Participants with a clinical diagnosis of Leber congenital amaurosis or early onset severe retinal degeneration whose phenotype is suggestive of biallelic RPE65-associated retinal degeneration will also be eligible for inclusion.
Inherited Retinal Degeneration Associated With RPGR Mutations cohort
Participants with genetically confirmed hemizygous RPGR sequence variants in male participants, or female participants with single heterozygous RPGR sequence variants or homozygous or compound heterozygous RPGR sequence variants will be included in this cohort. Participants with a clinical diagnosis of X-linked Retinitis Pigmentosa and X-linked cone-rod degeneration whose phenotype is suggestive of RPGR-associated retinal degeneration will also be eligible for inclusion.
Healthy non-myopic control cohort
Participants without myopia and without evidence of inherited retinal degeneration, will be included as one of the two control cohorts.
Myopic control cohort
Participants with myopia, defined as mean spherical equivalent refractive error of ≤ -1.00 dioptres and without evidence of inherited retinal degeneration will be included.
Sponsors
Collaborators: Massachusetts Eye and Ear Infirmary, TransMIT GmbH c/o Justus Liebig University Giessen, Moorfields Eye Hospital NHS Foundation Trust
Leads: University College, London

This content was sourced from clinicaltrials.gov